The value of observational research in liver diseases

Hepatology

Volumn 53, Issue 1, 2011, Pages 1-3

  Lindor, Rachel A ^a   Lindor, Keith D ^b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROFECOXIB;

CLINICAL RESEARCH; FOLLOW UP; HEALTH CARE POLICY; HEMOCHROMATOSIS; HEPATITIS C; HUMAN; LIVER DISEASE; NOTE; OBSERVATIONAL STUDY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); WILSON DISEASE;

HEPATITIS C; HUMANS; LIVER DISEASES; OBSERVATION; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT-CENTERED CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RESEARCH DESIGN;

EID: 78751517965     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24082     Document Type: Note

References (14)

1. Feuerstadt P, Bunim AL, Garcia H, Karlitz JJ, Massoumi H, Thosani AJ, et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology 2010; 51: 1137-1143.
2. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892.
3. Sawaya GF, Guirguis-Blake J, LeFevre M, Harris R, Petitti D. Update on the methods of the U.S. Preventive Services Task Force: estimating certainty and magnitude of net benefit. Ann Intern Med 2007; 147: 871-875.
4. Kavanagh BP. The grade system for rating clinical guidelines. PLoS Med 2009; 6: e1000094.
5. Sacks H, Chalmers TC, Smith H Jr. Randomized versus historical controls for clinical trials. Am J Med 1982; 72: 233-240.
6. Schneeweiss S, Patrick AR, Sturmer T, Brookhart MA, Avorn J, Maclure M, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 2007; 45: S131-S142.
7. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, et al. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med 2009; 151: 206-209.
8. Evans BJ. Seven pillars of a new evidentiary paradigm: the Food, Drug, and Cosmetic Act enters the genomic era. Notre Dame Law Rev 2010; 85: 419-524.
9. Etheredge LM. A rapid-learning health system. Health Aff (Millwood) 2007; 26: w107-w118.
10. Shah BR, Drozda J, Peterson ED. Leveraging observational registries to inform comparative effectiveness research. Am Heart J 2010; 160: 8-15.
11. Clancy C, Collins FS. Patient-Centered Outcomes Research Institute: the intersection of science and health care. Sci Transl Med 2010; 2: 37cm18.
12. Weems K. Doing more with less: a conversation with Kerry Weems. Health Aff (Millwood) 2009; 28: w688-w696.
13. Institute of Medicine. Learning What Works Best: The Nation's Need for Evidence on Comparative Effectiveness in Health Care. Washington, DC: National Academies Press; 2007.
14. Mohr P, Tunis S, Sabharwal R, Montgomery R, Bergthold L. The Comparative Effectiveness Research Landscape in the United States and Its Relevance to the Medicare Program. Baltimore, MD: Center for Medical Technology; 2010.